Humanin vs Metformin
A side-by-side research comparison of Humanin and Metformin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Humanin | Metformin |
|---|---|---|
| Full name | Humanin (HN) Mitochondrial-Derived Peptide | Metformin Hydrochloride |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved (off-label for longevity) |
| Mechanism | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. | Activates AMP-activated protein kinase (AMPK), inhibits mitochondrial complex I, reduces hepatic glucose output, and activates autophagy. Mimics the metabolic benefits of caloric restriction. |
| Molecular weight | 2,687 Da | 165.62 Da |
| Half-life | 4-6 hours | ~6.2 hours |
| Bioavailability | Moderate (SubQ) | ~50-60% oral |
| Typical dose | 1-5 mg | 500-1000 mg |
| Frequency | 3-5x per week | 1-2x daily |
| Route | Subcutaneous | Oral tablet (extended-release preferred) |
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
Metformin reported benefits
- AMPK activation
- Anti-aging cellular effects
- Cancer risk reduction
- Cardiovascular protection
- Blood sugar regulation
- Longevity support
Related comparisons
Research and educational reference only. Not medical advice.